Literature DB >> 8267678

Pharmacokinetics of glucosamine in man.

I Setnikar1, R Palumbo, S Canali, G Zanolo.   

Abstract

The pharmacokinetics of glucosamine sulfate (CAS 29031-19-4) was investigated in 6 healthy male volunteers (2 per administration route) using 14C uniformly labelled glucosamine sulfate and administering it in single dose by intravenous (i.v.), intramuscular (i.m.) or oral route. The results show that after i.v. administration the radioactivity due to glucosamine appears in plasma and is rapidly eliminated, with an initial t1/2 of 0.28 h. 1-2 h after administration the radioactivity due to glucosamine disappears almost completely and is replaced by a radioactivity originating from plasma proteins, in which glucosamine or its metabolites are incorporated. This radioactivity reaches a peak after 8-10 h and then declines with a t1/2 of 70 h. About 28% of the administered radioactivity is recovered in the urine of the 120 h following the administration and less than 1% is recovered in the feces. After i.m. administration similar pharmacokinetic patterns are observed. After oral administration a proportion close to 90% of glucosamine sulfate is absorbed. Free glucosamine is not detectable in plasma. The radioactivity incorporated in the plasma proteins follows pharmacokinetic patterns which are similar to those after i.v. or i.m. administration, but its concentration in plasma is about 5 times smaller than that after parenteral administration. The AUC after oral administration is 26% of that after i.v., or i.m. administration. The smaller plasma levels of radioactivity after oral administration are probably due to a first pass effect in the liver which metabolizes a notable proportion of glucosamine into smaller molecules and ultimately to CO2, water and urea.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267678

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  15 in total

Review 1.  Evidence of nutriceutical effectiveness in the treatment of osteoarthritis.

Authors:  J Y Reginster; V Gillot; O Bruyere; Y Henrotin
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  Complement activation after oxidative stress: role of the lectin complement pathway.

Authors:  C D Collard; A Väkevä; M A Morrissey; A Agah; S A Rollins; W R Reenstra; J A Buras; S Meri; G L Stahl
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 3.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Pain Headache Rep       Date:  2004-12

4.  Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness.

Authors:  B A Biggee; C M Blinn; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 5.  Glucosamine: a review of its use in the management of osteoarthritis.

Authors:  Anna J Matheson; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Effects of [3H]glucosamine concentration on [3H]chondroitin sulphate formation by cultured chondrocytes.

Authors:  Paula J Mroz; Jeremiah E Silbert
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 7.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

8.  A review of articular cartilage pathology and the use of glucosamine sulfate.

Authors:  C B James; T L Uhl
Journal:  J Athl Train       Date:  2001-10       Impact factor: 2.860

Review 9.  Role of glucosamine in the treatment for osteoarthritis.

Authors:  Jean-Yves Reginster; Audrey Neuprez; Marie-Paule Lecart; Nathalie Sarlet; Olivier Bruyere
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

10.  Non-NSAID over-the-counter (OTC) remedies for arthritis: good, bad or indifferent?

Authors:  M W Whitehouse; D E Butters
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.